Comments
Ranbaxy Laboratories today inked a licensing pact with EPIRUS Switzerland GmbH for BOW015, a biosimilar version of Infliximab, prescribed to treat rheumatoid arthritis.
EPIRUS Switzerland GmbH is a wholly owned subsidiary of Boston-based Epirus Biopharmaceuticals, Inc.
The product will be introduced in India and other emerging markets, the company said in a statement.
At present, there is no biosimilar version of Infliximab approved in India. Under the terms of the agreement, EPIRUS will develop and supply the product; and upon regulatory approval, Ranbaxy will market the same in India and other emerging markets.
Commenting on the partnership, Sanjeev I. Dani, Executive Vice-President & Head, Global Strategy, Ranbaxy, said: “We will utilise our strong front-end capabilities in making this product available in India and other parts of the world.”
Amit Munshi, President and CEO of EPIRUS, said: “We are very pleased to work with Ranbaxy to register and commercialise this important medicine. Ranbaxy has the right focus and infrastructure in these markets to effectively bring this product to the market.”
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.